Unknown

Dataset Information

0

Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and BRAF V600E mutation.

ABSTRACT: Liquid biopsies from cancer patients have the potential to improve diagnosis and prognosis. The assessment of surrogate markers of tumor progression in circulating extracellular vesicles could be a powerful non-invasive approach in this setting. We have characterized extracellular vesicles purified from the lymphatic drainage also known as exudative seroma (ES) of stage III melanoma patients obtained after lymphadenectomy. Proteomic analysis showed that seroma-derived exosomes are enriched in proteins resembling melanoma progression. In addition, we found that the BRAFV600E mutation can be detected in ES-derived extracellular vesicles and its detection correlated with patients at risk of relapse.

SUBMITTER: Garcia-Silva S 

PROVIDER: S-EPMC6504207 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and <i>BRAF</i> <sup><i>V600E</i></sup> mutation.

García-Silva Susana S   Benito-Martín Alberto A   Sánchez-Redondo Sara S   Hernández-Barranco Alberto A   Ximénez-Embún Pilar P   Nogués Laura L   Mazariegos Marina S MS   Brinkmann Kay K   Amor López Ana A   Meyer Lisa L   Rodríguez Carlos C   García-Martín Carmen C   Boskovic Jasminka J   Letón Rocío R   Montero Cristina C   Robledo Mercedes M   Santambrogio Laura L   Sue Brady Mary M   Szumera-Ciećkiewicz Anna A   Kalinowska Iwona I   Skog Johan J   Noerholm Mikkel M   Muñoz Javier J   Ortiz-Romero Pablo L PL   Ruano Yolanda Y   Rodríguez-Peralto José L JL   Rutkowski Piotr P   Peinado Héctor H  

The Journal of experimental medicine 20190411 5

Liquid biopsies from cancer patients have the potential to improve diagnosis and prognosis. The assessment of surrogate markers of tumor progression in circulating extracellular vesicles could be a powerful non-invasive approach in this setting. We have characterized extracellular vesicles purified from the lymphatic drainage also known as exudative seroma (ES) of stage III melanoma patients obtained after lymphadenectomy. Proteomic analysis showed that seroma-derived exosomes are enriched in pr  ...[more]

Similar Datasets

Unknown Anticancer effects of combinational treatment with BRAF<sup>V600E</sup> siRNA and PI3K pathway inhibitors in melanoma cell lines harboring BRAF<sup>V600E</sup>.
| S-EPMC6006476 | biostudies-literature
Unknown Vemurafenib enhances MHC induction in BRAF<sup>V600E</sup> homozygous melanoma cells.
| S-EPMC3583938 | biostudies-literature
Unknown M-CSF as a therapeutic target in BRAF<sup>V600E</sup> melanoma resistant to BRAF inhibitors.
| S-EPMC9470708 | biostudies-literature
Unknown BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma.
| S-EPMC3590666 | biostudies-other
Unknown KIT Suppresses BRAF<sup>V600E</sup>-Mutant Melanoma by Attenuating Oncogenic RAS/MAPK Signaling.
| S-EPMC5679278 | biostudies-literature
Unknown Extracellular Vesicles as Potential Prognostic Markers of Lymphatic Dysfunction.
| S-EPMC7261898 | biostudies-literature
Unknown Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival.
| S-EPMC7141227 | biostudies-literature
Unknown FBXW7 inactivation in a Braf<sup>V600E</sup> -driven mouse model leads to melanoma development.
| S-EPMC5668175 | biostudies-literature
Unknown Acquired and intrinsic resistance to vemurafenib in BRAF<sup>V600E</sup> -driven melanoma brain metastases.
| S-EPMC10761933 | biostudies-literature
Unknown Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAF<sup>V600E</sup> melanoma.
| S-EPMC4839378 | biostudies-literature